GMED
Globus Medical Inc
$79.58
▼ 0.7%Updated Today 12:11 PM ET
GMED at a glance — five pillars scored 0–100 from real filed financials.
Overall: Strong · 77/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▲ Up 34.8% over the last 12 months
Market Cap
$10.87B
P/E
18.53x
Forward P/E (est.)
13.23x
ROE
13.0%
Revenue Growth
23.5%
EPS Growth
221.2%
Profit Margin
18.9%
FCF Yield
3.0%
Debt / Equity
0x
ROIC
8.0%
Interest Coverage
—
Current Ratio
4.56x
Dividend Yield
—
Implied Growth (rev. DCF)
3.4%
Rating Score
77/100
Globus Medical Inc (GMED) is a large-cap company in the Health Care industry, part of the Health Care sector of the S&P 500, with a market value around $10.87B.
In its latest reported year it generated about $2.94B in revenue and $537.87M in net profit.
Our model rates GMED Strong (77/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what GMED's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. GMED trades near $79.58, below its 50-day average ($82.43) and 200-day average ($82.00). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 49 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. GMED's is $3.39 (~4.3% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month GMED found buyers near $74.67 (support) and sellers near $86.34 (resistance); its 52-week range is $51.79–$101.40. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.2× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
4Y CAGR
32.3%
Revenue moved from $563.99M in 2016 to $2.94B in 2025, a 20.1% compound annual growth rate. The most recent year grew a strong 23.5% year over year. Consistent top-line growth is one sign of healthy demand.
Gross Margin
67.9%
Operating Margin
16.3%
Net Margin
18.3%
ROE
13.0%
Globus Medical Inc keeps about 18.9% of each sales dollar as net profit, with a 67.9% gross margin and 16.3% operating margin. Return on equity is 13.0% and return on invested capital about 8.0%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
—
Net Debt
—
Net Debt / EBITDA
—
Debt / Equity
0x
Leverage: debt-to-equity is 0.0x, with a current ratio of 4.6x. That is a conservative balance sheet — a cushion in downturns.
Operating CF
$753.45M
Free Cash Flow
$588.77M
FCF Margin
20.0%
In the latest year Globus Medical Inc produced about $753.45M of operating cash flow and $588.77M of free cash flow after capital spending. That is a free-cash-flow yield of about 3.0% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
18.53x
P/S
3.7x
P/B
2.57x
EV / EBITDA
13.62x
GMED trades at 18.5x trailing earnings (about 13.2x on estimated forward earnings), 3.7x sales, and 2.6x book value. Reverse-engineering today's price implies the market expects roughly 3.4% long-term free-cash-flow growth. That is a fairly typical valuation for a profitable company.
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
DCF fair value / share
$179.61
Current price
$79.58
Starting FCF (latest 10-K)
$588.77M
Growth, years 1–5
20.0%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Where GMED sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 53 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How GMED stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (198 S&P 500 companies), GMED ranks #3 of 198 by our overall rating. It trades at a discount versus the sector on earnings (18.5x P/E vs. 25.5x median) with a lower return on equity (13.0% vs. 14.5%) and faster revenue growth (23.5% vs. 7.6%).
P/E vs sector
18.5x
median 25.5x
ROE vs sector
13.0%
median 14.5%
Growth vs sector
23.5%
median 7.6%
Sector rank
#3
of 198 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 198 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $79.58 today · expected CAGR 9% – 21%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $3.61B | $4.45B | $5.47B | $6.73B | $8.27B |
| Net income | $650.68M | $800.34M | $984.41M | $1.21B | $1.49B |
| EPS | $4.79 | $5.90 | $7.25 | $8.92 | $10.97 |
| Share price (low) | $52.73 | $64.85 | $79.77 | $98.12 | $120.69 |
| Share price (high) | $91.07 | $112.02 | $137.79 | $169.48 | $208.46 |
| CAGR (low–high) | -34% / 14% | -10% / 19% | 0% / 20% | 5% / 21% | 9% / 21% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for GMED:
- Revenue is growing 23.5% a year, a sign of real demand.
- High net margins (18.9%) point to pricing power or efficiency.
- A conservative balance sheet (debt/equity 0.0x) lowers risk.
- Our model's overall read is Strong (77/100).
The case against GMED:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: Globus Medical Inc is a large-cap health care business still growing nicely, with solid profitability, and a sound balance sheet. It trades at 18.5x earnings, which our model scores Strong (77/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
GMED — frequently asked questions
Is GMED a good stock to buy?
We don't give buy or sell advice. Our model rates Globus Medical Inc Strong (77/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is GMED's rating on The Stocks School?
Globus Medical Inc currently scores 77/100 (Strong) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does GMED's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Globus Medical Inc's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for GMED calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this GMED analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell GMED. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.